Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Coenzyme Q10 & Atorvastatin
10 mg Atorvastatin daily plus 100 mg Coenzyme Q10 pearl supplement twice daily for four months.
Atorvastatin
Coenzyme Q10
Atorvastatin & placebo
10 mg Atorvastatin daily and the placebo of Coenzyme Q10 pearl for four months.
Atorvastatin
placebo for coenzyme Q10
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin
Coenzyme Q10
placebo for coenzyme Q10
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ejection Fraction less than 40 percent
* Compensated heart failure without hospital admission during previous three months
* No change in type and dose of medications in the last months
* New York Heart Association Function Class 2 to 4
Exclusion Criteria
* Active myocarditis
* Active pericarditis
* Uncontrolled hypertension
* Hepatic failure(Child B,C)
* Pulmonary failure
* Renal failure
* Heart failure with KILLIP classification 3 and 4
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Isfahan University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amin Nemati
member of Isfahan Medical Students Research Committee
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Masoud Pourmoghaddas, cardiologist
Role: STUDY_DIRECTOR
Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vice Chancellery for Research of Isfahan University of Medical Sciences, Isfahan, Iran
Isfahan, Isfahan, Iran
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Amin Nemati, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
392219
Identifier Type: -
Identifier Source: org_study_id